Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Akeso.

    Client Virtual Booth

    AKESO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Akeso
    China Flag
    Country
    Country
    China
    Address
    Address
    No. 6, Shennong Road, Torch Development Zone, Zhongshan City, Guangdong Province 528437
    Telephone
    Telephone
    0760-8987 3998
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.akesobio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/akeso-bio/
    Twitter
    Twitter
    https://twitter.com/AkesoInc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy Versus Tislelizumab Combined with Chem...

    Details:

    AK104 (cadonilimab) is a PD-1/CTLA-4 bi-specific antibody which is being investigated in phase 3 in combination with chemotherapy (Carboplatin, Pemetrexed, Paclitaxel) for PD-L1 negative non-small cell lung cancer.


    Lead Product(s): Cadonilimab,Carboplatin,Pemetrexed

    Therapeutic Area: Oncology Product Name: AK104

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 06, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer

    Details:

    AK104 (cadonilimab) is a bispecific antibody that targets both PD-1 & CTLA-4. It is under phase 3 clinical development in combination with chemotherapy for the treatment of unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.


    Lead Product(s): Cadonilimab,Capecitabine,Oxaliplatin

    Therapeutic Area: Oncology Product Name: AK104

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line...

    Details:

    AK104 (cadonilimab) is a PD-1/CTLA-4 bi-specific antibody approved and marketed for use in combination with chemotherapy as first-line therapy for advanced gastric or gastroesophageal junction cancer (GC/GEJC).


    Lead Product(s): Cadonilimab

    Therapeutic Area: Oncology Product Name: AK104

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 07, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

    Details:

    AK117 (ligufalimab) is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect, which is investigated in Combination with Azacitidine for the treatment of Myelodysplastic Syndromes.


    Lead Product(s): Ligufalimab,Azacitidine

    Therapeutic Area: Oncology Product Name: AK117

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced ...

    Details:

    SMT112 (ivonescimab) is a potential first-in-class investigational PD-1/VEGF bi-specific antibody, which is investigated for the treatment of first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.


    Lead Product(s): Ivonescimab

    Therapeutic Area: Oncology Product Name: SMT112

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Summit Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 29, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA

    Details:

    AK112/SMT112 (ivonescimab) is a potential first-in-class investigational PD-1/VEGF bi-specific antibody, which is investigated for the treatment of first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.


    Lead Product(s): Ivonescimab

    Therapeutic Area: Oncology Product Name: AK112

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 25, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA

    Details:

    AK101 (ebdarokimab) is a novel fully human Interleukin-12/Interleukin-23 monoclonal antibody, which is investigated for the treatment of adult patients with moderate-to-severe plaque-type psoriasis.


    Lead Product(s): Ebdarokimab

    Therapeutic Area: Dermatology Product Name: AK101

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 24, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

    Details:

    SMT112 (Ivonescimab) is a potential first-in-class investigational PD-1/VEGF bi-specific antibody, which is investigated for the treatment of first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.


    Lead Product(s): Ivonescimab

    Therapeutic Area: Oncology Product Name: SMT112

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Summit Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    NMPA Accepted Akeso's Ebronucimab (PCSK9) Marketing Application in two Cardiovascular Indications

    Details:

    NMPA has accepted its NDA for its fully human anti-PCSK9 monoclonal antibody AK102 (ebronucimab) for 2 indications 1) primary hypercholesterolemia and mixed hyperlipidemia, and 2) heterozygous familial hypercholesterolemia.


    Lead Product(s): Ebronucimab

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: AK102

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: AD Pharmaceuticals

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 01, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer

    Details:

    AK104 (cadonilimab) is a PD-1/CTLA-4 bi-specific antibody approved and marketed for use in combination with chemotherapy as first-line therapy for advanced gastric or gastroesophageal junction cancer (GC/GEJC).


    Lead Product(s): Cadonilimab

    Therapeutic Area: Oncology Product Name: AK104

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 14, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search